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Abstract
MicroRNAs are small noncoding RNAs that function to control gene expression. These small RNAs have been
shown to contribute to the control of cell growth, differentiation and apoptosis, important features related to
cancer development and progression. In fact, recent studies have shown the utility of microRNAs as cancer-related
biomarkers. This is due to the finding that microRNAs display altered expression profiles in cancers versus normal
tissue. In addition, microRNAs have been associated with cancer progression. In this review, the mechanisms to
alter microRNA expression and their relation to cancer will be addressed. Moreover, the potential application of
microRNAs in clinical settings will also be highlighted. Finally, the challenges regarding the translation of research
involving microRNAs to the clinical realm will be discussed.
Review
The Biogenesis and Physiological Functions of MicroRNAs
MicroRNAs are a group of small noncoding functional
RNAs that are approximately 22 nucleotides in length [1].
MicroRNAs are transcribed by RNA polymerase II or III
as longer primary microRNAs termed pri-microRNA. This
molecule is then modified in the nucleus through capping
and polyadenylation and subsequently cleaved into smaller
segments by Drosha, an RNAseIII enzyme. This forms a
hairpin precursor of approximately 60-70 nucleotides,
termed pre-microRNA, which is exported to the cyto-
plasm and modified by another enzyme, the RNAseII
endonuclease, Dicer, to form a duplex of mature micro-
RNA. One of the microRNA strands of the duplex is
loaded onto the RNA-induced silencing complex (RISC)
where it is then able to either cleave RNA targets or
repress protein translation dependent upon its comple-
mentarity to the target mRNA. Through their binding to
target mRNA sequences, microRNAs have a large number
of biologically diverse functions. They have the capacity to
control the expression of many downstream genes which
can affect several cell regulatory pathways, such as cell
growth, differentiation, mobility and apoptosis.
The Detection of MicroRNA Expression
Several techniques have been developed to examine
microRNA expression. One of the most predominant
methods in the literature is microRNA microarrays.
Microarray technology offers a powerful high-throughput
tool to monitor the expression of thousands of micro-
RNAs at once [2]. Quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) is another reliable
and highly sensitive technique for microRNA detection,
which is simple and robust, and only requires very small
amounts of input total RNA [3]. Standard northern blot-
ting has also been employed to detect and validate micro-
RNA expression levels [4]. In addition, techniques are
available to detect microRNAs by in situ hybridization.
Although various microRNAs have been detected from
tissue sources, these methods require invasive techniques
to collect the starting material. Therefore, procedures
have also been established to measure microRNA expres-
sion in blood products to enable clinical feasibility of
microRNA measurement [5]. Most recently, the advent
of next generation sequencing technologies allows for the
measurement of the absolute abundance as well as the
discovery of novel microRNAs. These various techniques
have allowed researchers to measure the levels of many
microRNAs and determine how alterations in their
expression level are associated with particular phenotypes
and how they can be clinically utilized. These aspects of
microRNA expression levels are discussed in the remain-
der of this review.
The Role of MicroRNAs in Cancer
S i n c et h e i rd i s c o v e r yi nn e m a t o d e s ,m i c r o R N A sh a v e
been shown to play a role in cancer (Table 1). The
expression patterns, function and regulation of micro-
RNAs in normal and neoplastic human cells are largely
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at fragile sites, common break-points or regions of
amplification or loss of heterozygosity reveal that they
may play significant roles in human carcinogenesis.
Other possible mechanisms of altered microRNA
expression include defective microRNA processing or
post-transcriptional regulation, germ-line or somatic
mutation and epigenetic changes such as methylation
[6-9]. The abnormal expression of several microRNAs
have been observed in Burkitt’s lymphomas, B cell
chronic lymphocytic leukemia (CLL) and in many solid
cancer types, including breast, liver, lung, ovarian, cervi-
cal, colorectal and prostate [10-21]. Functional analysis
has revealed the downregulation of PTEN by miR-21,
the tumor suppressor function of the let-7 family and
the oncogenic function of the miR17-92 cluster [22-24].
The biological and clinical relevance of microRNA
expression patterns have been established in human B
cell CLL and solid tumors, including breast cancers
[11,15,25].
Each microRNA has the distinct capability to poten-
tially regulate the expression of hundreds of coding
genes and thereby modulate several cellular pathways
including proliferation, apoptosis and stress response
[26]. Their altered expression in cancer can be a causa-
tive factor or perhaps a consequence of the disease
state. Dependent upon the nature of their target gene(s),
microRNAs may function as tumor suppressors by
downregulating target oncogenes (e.g. let-7 g, miR-15/16
and miR-34) or as oncogenes by negatively controlling
genes that regulate tumor cell differentiation and apop-
tosis (e.g. miR-155 and miR-21) [27]. Alternatively,
changes in microRNA expression may be a downstream
effect of potent oncogenes or tumor suppressors in the
carcinogenesis process such as the modulation of miR-
34 by p53 [28]. MicroRNAs have also been shown to
play a role in cancer progression through the modula-
tion of cellular adhesion, cell matrix and signaling activ-
ities [29-33]. In addition, microRNAs play roles in
regulating the expression of hypoxia-related genes,
vascular endothelial growth factors [34-36].
The Clinical Applications of MicroRNAs
Since the expression of microRNAs are altered in can-
cers, it is thought that they may function as suitable bio-
markers for disease state and progression. Recent studies
indicate that expression profiling of microRNAs is a
superior method for cancer subtype classification and
prognostication [10,11,20]. The application of micro-
RNA screening for the purposes of diagnosis and prog-
nosis are briefly described below.
Diagnostic MicroRNAs
Multiple reports have noted the utility of microRNAs
for the diagnosis of cancer [37,38]. microRNA expres-
sion profiles have been used to distinguish tumor from
normal samples, identification of tissue of origin for
tumors of unknown origin or in poorly differentiated
tumors and to distinguish different subtypes of tumors.
Sample datasets have been stratified to show that certain
alterations of microRNAs occur in patients at an early
stage of cancer and thus may be quite useful for early
detection. Large tissue specimens are not needed for
accurate MicroRNA detection since their expression can
be easily measured in biopsy specimens. Although the
majority of these studies have used tissue to assess
microRNA levels, recent studies have shown that micro-
R N A sc a nb em e a s u r e di nf o r m a l i nf i x e dp a r a f f i n
embedded (FFPE) tissues [39]. Given the invasive nature
of fresh/frozen tissue collection and the availability of
FFPE, this serves as a major advance in the feasibility of
measuring microRNA levels for the purposes of diagno-
sis. Recent studies have also shown that microRNAs can
Table 1 MicroRNAs Associated with Cancer
Cancer Type Human microRNA Potential Function References





Colon Cancer miR-21; miR-34a OncomiR; Tumor
Suppressor
[41,77-79]





Pancreatic Cancer miR-196a, miR196b OncomiR [82-84]





Ovarian Cancer miR-141, miR-200a/b/c;






miR-21, miR-224, miR-34a, miR221, miR-222, miR-106, miR-303; miR26a/b, let-7g, miR-




Thyroid Cancer miR-146, miR-221, miR-222,
miR-181b, miR-155, miR-224
OncomiR [91-93]
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utilizing microRNA screening via less invasive blood-
based mechanisms. In addition, mature microRNAs are
relatively stable. These phenomena make microRNAs
superior molecular markers and targets for interrogation
and as such, microRNA expression profiling can be uti-
lized as a tool for cancer diagnosis [10,40].
Prognostic MicroRNAs
The potential clinical utility of microRNA extends beyond
the realm of diagnosis to other important clinical measures
such as prognosis and treatment response. A series of pub-
lications has shown that microRNAs are useful indicators
of clinical outcome in a number of cancer types [10,40-45].
In addition, microRNAs have been shown to play a predic-
tive role in determining the tendency for recurrence and
metastasis [46-50]. These microRNA alterations have not
only been found in tumor specimens, but have also been
observed in surrounding non-cancerous tissue, indicating
that microRNAs may also serve to detect alterations in the
cancer microenvironment [45,51,52]. microRNAs have also
been shown as useful indicators of which patient groups
may respond better to a particular treatment regimen. An
example of this was shown for liver cancer patients,
whereby miR-26 expression could be used to stratify
patients for IFN treatment [53]. The full potential of micro-
RNAs as prognostic factors awaits the results of larger
prospective studies.
The Therapeutic Application of MicroRNAs
As noted above, several microRNAs have been shown to
be altered in disease states when compared to normal
specimens. Whether this differential expression occurs as
a consequence of the pathological state or whether the
disease is a direct cause of this differential expression is
currently unknown. Nonetheless, since microRNAs are
deregulated in cancer, it is thought that normalization of
their expression could be a potential method of interven-
tion. In this vein, several therapeutic mechanisms have
been put forth and are described below (Table 2).
Strategies for microRNA reduction
The rules of Watson and Crick base-pairing guide the
binding of microRNAs to their target sites. In order to cir-
cumvent this interaction, anti-microRNA oligonucleotides
(AMOs) have been generated to directly compete with
endogenous microRNAs [54]. However, the ability of
AMOs to specifically inactivatee n d o g e n o u st a r g e t sh a s
been shown to be quite inefficient. Thus, several modifica-
tions of AMOs have been generated to improve their
effectiveness and stability such as the addition of 2’-O-
methyl and 2’-O-methoxyethyl groups to the 5’ end of the
molecule [55]. Studies have shown that targeting of miR-
21, a microRNA that is overexpressed in many cancer
types, by such methods effectively reduced tumor size in a
xenograft mouse model based on MCF-7 cells [56]. AMOs
conjugated to cholesterol (antagomirs) have been also
been generated and have been described to efficiently inhi-
bit microRNA activity in-vivo [57]. In addition, locked-
nucleic-acid antisense oligonucleotides (LNAs) have been
designed to increase stability and have been shown to be
highly aqueous and exhibit low toxicity in-vivo [58]. In
gliomas, this method has been effectively used to comple-
tely eradicate miR-21 [59]. Another method for reducing
the interaction between microRNAs and their targets is
the use of microRNA sponges. These sponges are syn-
thetic mRNAs that contain multiple binding sites for an
endogenous microRNA. Sponges designed with multi-
meric seed sequences have been shown to effectively
repress microRNA families sharing the same seed
sequence [60]. Although microRNA sponges perform as
well as chemically modified AMOs in-vitro, their efficacy
in-vivo remains to be determined.
Although these oligonucleotide-based methods have
been shown to work, they do elicit off-target side effects
and unwanted toxicity. This is due to the capability of
microRNAs to regulate hundreds of genes. A strategy
called miR-masking is an alternative strategy designed to
combat this effect. This method utilizes a sequence with
perfect complementarity to the target gene such that
duplexing will occur with higher affinity than that between
the target gene and its endogenous microRNA. The caveat
of this approach is that the choice of target gene must be
specific in order to effectively reduce the interaction. This
gene-specific, microRNA interfering strategy has been
shown to reduce the activities of miR-1, miR-133 and
miR-430 in several model systems [61,62]. Another strat-
egy to increase specificity of effects is the use of small
Table 2 Strategies to Employ MicroRNAs in the Clinic
Strategy Modulator Delivery Clinical Utility References
Inhibition of mature microRNA cluster microRNA sponge Sponge plasmid vector Silence oncomiR cluster [60]
Inhibition of mature microRNA 2’OME-AMOs RNA-Liposome Complex Silence OncomiR [94]
Inhibition of mature microRNA 2’MOE AMOs Oligonucleotide-Liposome Complex Silence OncomiR [95,96]
Inhibition of pri-microRNA AMOs Oligonucleotide-Liposome Complex Silence miR cluster [97,98]
Inhibition of mature microRNA LNA-antagomiR Unconjugated Silence OncomiR [99]
Silence selected target Synthetic microRNAs Conjugation Tumor Suppressor Function [100,101]
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zene, for example, has been identified as a specific and effi-
cient inhibitor of miR-21 [63]. Although the effectiveness
of such inhibitors awaits exploration in-vivo, they are
potentially promising tools for cancer therapy.
Strategies to overexpress microRNAs
Elevating the expression of microRNAs with tumor sup-
pressive roles is a strategy to restore tumor inhibitory
functions in the cell. This can be achieved through the
use of viral or liposomal delivery mechanisms [64,65].
Several microRNAs have been introduced to cells via
this methodology, including miR-34, miR-15, miR-16
and let-7 [66-69]. Systemic administration of miR-26, a
tumor suppressive microRNA in HCC, using adeno-
virus-associated virus (AAV) in an animal model of
HCC, results in inhibition of cell proliferation and
tumor-specific apoptosis [70]. This approach reduces
toxicity since AAV vectors do not integrate into the
host genome and eventually are eliminated. Although
viral vector-directed methods show high gene transfer
efficiency, they lack tumor targeting and residual viral
elements can elicit immunonogenic effects. This has led
to the development of non-viral methods of gene trans-
fer such as cationic liposome mediated systems. These
lipoplexes are promising, but they lack tumor specificity
and have relatively low transfection efficiency when
compared to viral vectors.
MicroRNA mimics have also been used to increase
microRNA expression. These small, chemically modified
double-stranded RNA molecules mimic endogenous
mature microRNA. These mimics are now commercially
available and promising results have been reported with
systemic delivery methods using lipid and polymer-
based nanoparticles [71-73]. Since these mimics do not
have vector-based toxicity, they are promising tools for
therapeutic treatment of tumors.
Conclusions
As described above, there have been many new technolo-
gical advances to utilize microRNAs as therapeutic tools.
In order to fully achieve this however, conceptual and
technical issues still need to be overcome. Since micro-
RNAs can potentially inhibit many genes, a major hurdle
to overcome is specificity. Partial complimentarity can
lead to off-target gene silencing or up-regulation and thus
undesired biological effects. Given the multi-gene targets
of a single microRNA, the magnitude of an off-target asso-
ciation may be quite large. Thus, it remains important to
comprehensively evaluate each specific microRNA-
mediated therapy. Conversely, it may be useful to target
multiple members of a gene family with a single micro-
RNA. Such strategies are currently underway to design
small multiple target artificial (SMART) microRNAs to
simultaneously target members of a single gene family,
such as E2F [74]. A more thorough understanding of
microRNA biology and function will allow for more suita-
ble strategies. Another issue that warrants future study is
the efficiency of delivery of microRNA to specific sites.
One needs to achieve a certain amplitude of target gene
modulation and to maximize the number of cells that
receive therapeutic microRNA at target sites. This effect
also needs to be long-lasting with minimal toxicity to the
recipient. Further advances in the area of drug delivery
will no doubt improve upon the current tools of the trade.
Once a provocative finding in a worm-based model,
microRNAs have now become a grand player in the
field of biological science and clinical therapy. Research
within the last few decades has significantly added to
our knowledge of the biogenesis and function of micro-
RNAs. These studies have shown that microRNAs play
a large and key role in many aspects of cancer biology
and that alteration of their expression can have pro-
found effects on cancer phenotypes. The translation of
these findings to in-vivo models and clinical studies will
unquestionably lead to greater insight into their utility
in clinical settings. The notion of microRNAs as thera-
peutic agents is in the first phases and is at the cusp of
providing major advances in research and to enhancing
the tools available to alleviate cancer.
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